A Study of ERY974 in Patient With Advanced Solid Tumors

Status: complete

This is the open label, multicenter Phase 1 study which consists of a dose escalation to determine the maximum tolerated dose (MTD) and cohort expansion to obtain a preliminary evaluation of anti-tumor activity. ERY974 is intravenously injected to patients with Glypican 3 positive advanced solid tumors until unacceptable toxicity or disease progression.

Inclusion Criteria

Male or female patient with Glypican 3 positive advanced solid tumor not amenable to standard therapy or for which standard therapy is not available or not indicated
Measurable tumor
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
Adequate bone marrow, liver, and renal function
Adequate coagulation status

Exclusion Criteria

Patients with more than a single brain metastasis ( >1 cm)
Patients with acute or chronic infection
Major surgery within 28 days
Pregnant or lactating women
Patients with interstitial pneumonitis
Patients require regular ascites/pleural effusion drainage

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02748837.

State:

United States

Florida

Tampa

Moffitt Cancer Center

Status: Active

Contact: Khaldoun Almhanna

Phone: 313-576-8712

North Carolina

Durham

Duke University Medical Center

Status: Active

Name Not Available

Texas

Houston

M D Anderson Cancer Center

Status: Approved

Name Not Available

Have a question?
We're here to help

Chat with us: LiveHelp
Call us: 1-800-4-CANCER
(1-800-422-6237)

Which trials are right for you?

Use the checklist in our guide to gather the information you’ll need.

A Study of ERY974 in Patient With Advanced Solid Tumors

Description

Eligibility Criteria

Locations & Contacts

Trial Objectives and Outline

Trial Phase & Type

Lead Organization

Trial IDs

Have a question?We're here to help

Which trials are right for you?

Have a question?
We're here to help